Renal oncocytoma (RO) is an uncommon and non-cancerous tumor of the kidney that arises from the intercalated cells of the collecting ducts. From diagnostic evaluations to the creation of novel therapeutics for renal oncocytoma, Protheragen offers a comprehensive range of services.
Overview of Renal Oncocytoma (RO)
Renal oncocytoma (RO) is a rare benign oncological tumor of the kidney which accounts for roughly 3-7% of all renal masses. Patients are usually older, and ROs peak in the seventh decade of life. ROs usually are found incidentally while imaging the abdomen for other reasons. Their description includes well-circumscribed, tan- or mahogany-colored masses with a central stellate scar. Histological features of ROs include eosinophilic granular cytoplasm, nuclear features with prominent nucleoli, and a nested pattern. Although benign, these tumors can occasionally become aggressive with features of vascular or perinephric fat invasion, although these features do not always mean a poor prognosis.
Fig.1 Estimates of mean annual change in tumor diameter (mm/year) for oncocytomas on active surveillance (AS). (Edwards F.,
et al., 2025)
Pathogenesis of Renal Oncocytoma (RO)
The development of renal oncocytoma is not fully understood, although multiple hypotheses have been put forward based on the histological and molecular research. One important branch of the hypotheses focuses on the failure of selective autophagy due to the block of mitochondrial protein mutations in the cell's nucleus and mitochondria. Such failure results in excess defective mitochondria, which is a feature of RO cells. Moreover, the chromophobe renal cell carcinoma (RCC) is thought to be closely related to renal oncocytoma (RO) and is intercalated distantly in the renal tubules. The RO cell's mitochondria also account for the RO cell's granular appearance microscopically and their strong response to certain imaging dyes.
Diagnostics Development for Renal Oncocytoma (RO)
Imaging Techniques
Imaging plays a crucial role in the initial evaluation of renal masses, including ROs. Computed tomography (CT) and magnetic resonance imaging (MRI) are the most commonly used modalities. CT scans typically show well-circumscribed, homogeneous masses with a central stellate scar. MRI can provide additional information about the tumor's architecture and the presence of a central scar. However, neither CT nor MRI can definitively distinguish RO from RCC, necessitating further diagnostic procedures.
Histopathological Analysis
Histopathological examination remains the gold standard for diagnosing RO. Key features include eosinophilic granular cytoplasm, regular nuclei with prominent nucleoli, and a nested architectural pattern. Immunohistochemical staining, such as CK7 and KIT (CD117), can aid in differentiating RO from other renal tumors. Electron microscopy can also be useful in identifying the high mitochondrial content in RO cells.
Therapeutics Development for Renal Oncocytoma (RO)
- Ablation Therapies
Ablation therapies, such as cryoablation and radiofrequency ablation (RFA), are becoming viable alternatives to surgery for small, asymptomatic renal oncocytomas. These techniques offer less invasive, cost-effective solutions with lower complication rates. They involve the localized destruction of tumor tissue through thermal energy, either via freezing (cryoablation) or heat (RFA). These therapies are particularly beneficial for patients with comorbidities or those wishing to avoid the risks of surgery.
- Active Surveillance
Given the slow growth rate of RO, active surveillance is often a recommended management strategy, especially for smaller, asymptomatic tumors. This approach involves regular monitoring through imaging, with intervention initiated only if there is evidence of tumor growth or symptom progression. Studies have shown that RO, despite potential for growth, generally follows a benign course with an excellent prognosis.
- Chemotherapy and Targeted Therapies
There is limited data on the use of chemotherapy for RO, as the tumor is typically benign. However, in cases where RO is associated with hybrid tumors or exhibits aggressive features, targeted therapies may be considered. These therapies could include agents that target specific molecular pathways involved in mitochondrial dysfunction, such as those regulating autophagy or oxidative stress.
Our Services
Protheragen offers comprehensive diagnostic and therapeutic development services tailored to the unique needs of renal oncocytoma research. These services encompass a broad spectrum, including advanced imaging, histopathological analysis, and preclinical therapeutic testing.
Disease Models
- Scaffold-Free Tumoroid Models
- Genetically Engineered Mouse (GEM) Models
- Ferric Nitrotriacetate (Fe-NTA)-Induced Rat Models
- Renal Oncocytoma Xenograft Models
Preclinical research services at Protheragen focus on understanding the molecular and metabolic pathways that drive renal oncocytoma progression. These services include the development of animal models, testing of new drug candidates, and the assessment of therapeutic efficacy. Through rigorous in vitro and in vivo studies, Protheragen aims to provide a deeper understanding of RO's pathogenesis and develop targeted therapeutics. If you are interested in our services, please feel free to contact us.
References
- Abdessater, Maher, et al. "Renal oncocytoma: an algorithm for diagnosis and management." Urology 143 (2020): 173-180.
- Edwards, Francesco, et al. "Natural history of treated and untreated renal oncocytoma: a systematic review and meta-analysis." BJU international (2025).
- Rajagopal, Ragaul, Edzhem Yoztyurk, and Kapilraj Ravendran. "Renal oncocytoma: a systematic review of its metastatic features." Cureus 16.10 (2024).
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
